Tango Therapeutics, Inc.

NasdaqGM:TNGX Stock Report

Market Cap: US$4.4b

Tango Therapeutics Management

Management criteria checks 2/4

Tango Therapeutics' CEO is Malte Peters, appointed in Jan 2026, has a tenure of less than a year. directly owns 0.008% of the company’s shares, worth $343.46K. The average tenure of the management team and the board of directors is 1.3 years and 5.3 years respectively.

Key information

Malte Peters

Chief executive officer

US$1.2m

Total compensation

CEO salary percentagen/a
CEO tenureless than a year
CEO ownership0.008%
Management average tenure1.3yrs
Board average tenure5.3yrs

Recent management updates

Recent updates

Analysis Article • Jun 17

Tango Therapeutics (TNGX) Stock Could Be 39% Below Fair Value After Trial Data And Offering

Tango Therapeutics (TNGX) drew fresh attention after positive Phase 1/2 vopimetostat data in difficult pancreatic and lung cancer settings, coinciding with a completed US$600 million follow on equity offering. See our latest analysis for Tango Therapeutics. The recent vopimetostat data and the US$600 million follow on offering have arrived alongside strong momentum in Tango Therapeutics’ stock, with a year to date share price return of 260.13% and a 1 year total shareholder return that is...
Seeking Alpha • Jun 09

Tango Therapeutics: Combo Data With Revolution's RAS Inhibitor Whets Risk Appetite

Summary Tango Therapeutics, Inc. surged over 625% since January 2025, driven by best-in-class Phase 1/2 data for vopimetostat in combination with RAS inhibitors. Vopimetostat plus daraxonrasib achieved a 92% objective response rate in MTAP-deleted, RAS-mutant metastatic pancreatic cancer, supporting rapid advancement to Phase 3. TNGX is now exclusively focused on PRMT5 inhibitors, with robust funding—$380M cash plus a $500M equity raise—supporting operations into 2028. I maintain a Hold rating for TNGX, citing the need for clarity on Tango’s and Revolution’s strategic paths, upcoming monotherapy data, and potential M&A interest. Read the full article on Seeking Alpha
Analysis Article • Jan 19

Tango Therapeutics, Inc.'s (NASDAQ:TNGX) 53% Price Boost Is Out Of Tune With Revenues

Tango Therapeutics, Inc. ( NASDAQ:TNGX ) shareholders have had their patience rewarded with a 53% share price jump in...
Analysis Article • Dec 05

Subdued Growth No Barrier To Tango Therapeutics, Inc. (NASDAQ:TNGX) With Shares Advancing 32%

Despite an already strong run, Tango Therapeutics, Inc. ( NASDAQ:TNGX ) shares have been powering on, with a gain of...
Analysis Article • Sep 17

Tango Therapeutics, Inc. (NASDAQ:TNGX) Investors Are Less Pessimistic Than Expected

With a price-to-sales (or "P/S") ratio of 33.7x Tango Therapeutics, Inc. ( NASDAQ:TNGX ) may be sending very bearish...
Analysis Article • May 15

US$10.43: That's What Analysts Think Tango Therapeutics, Inc. (NASDAQ:TNGX) Is Worth After Its Latest Results

The analysts might have been a bit too bullish on Tango Therapeutics, Inc. ( NASDAQ:TNGX ), given that the company fell...
Analysis Article • Apr 14

Little Excitement Around Tango Therapeutics, Inc.'s (NASDAQ:TNGX) Revenues As Shares Take 28% Pounding

Unfortunately for some shareholders, the Tango Therapeutics, Inc. ( NASDAQ:TNGX ) share price has dived 28% in the last...
Analysis Article • Apr 04

Here's Why We're Watching Tango Therapeutics' (NASDAQ:TNGX) Cash Burn Situation

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Analysis Article • Feb 28

Tango Therapeutics, Inc. (NASDAQ:TNGX) Looks Inexpensive After Falling 30% But Perhaps Not Attractive Enough

To the annoyance of some shareholders, Tango Therapeutics, Inc. ( NASDAQ:TNGX ) shares are down a considerable 30% in...
Analysis Article • Feb 28

Tango Therapeutics, Inc. (NASDAQ:TNGX) Not Doing Enough For Some Investors As Its Shares Slump 30%

To the annoyance of some shareholders, Tango Therapeutics, Inc. ( NASDAQ:TNGX ) shares are down a considerable 30% in...
Seeking Alpha • Jan 23

Tango Therapeutics: Chance For A Short Squeeze

Summary Tango Therapeutics is a growing cancer drug development company with partners such as Gilead Sciences. Given the high short interest and the low number of shares outstanding, I expect a short squeeze to occur, which could lead to an increase in TNGX's share price thereafter. Despite the negative sentiment, recent institutional selling and call option activity suggest potential value accumulation and positive momentum for TNGX. I decided to buy OTM call options on TNGX due to the low implied volatility. Read the full article on Seeking Alpha
Analysis Article • Dec 05

Is Tango Therapeutics (NASDAQ:TNGX) In A Good Position To Invest In Growth?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Oct 31

Tango Therapeutics, Inc.'s (NASDAQ:TNGX) 26% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio

Unfortunately for some shareholders, the Tango Therapeutics, Inc. ( NASDAQ:TNGX ) share price has dived 26% in the last...
Seeking Alpha • Sep 10

Tango Therapeutics: Amgen Missteps Devalue PRMT5 Candidates Ahead Of Critical Data

Summary Tango Therapeutics, Inc. offers high-risk, high-reward exposure to PRMT5-inhibitor drugs, with two candidates, TNG908 and TNG462, targeting MTAP-deleted cancers, a substantial market opportunity. TNGX stock volatility is influenced by competitors' PRMT5 data, with recent fluctuations driven by Amgen and Mirati's clinical results. Tango's financial stability is supported by >$300M in cash, a Gilead partnership, and a funding runway until 2027, covering key clinical readouts. Despite the high risk, Tango's differentiated approach and potential blockbuster candidates make TNGX stock an intriguing speculative buy ahead of critical data readouts. Read the full article on Seeking Alpha
Analysis Article • Sep 01

What Tango Therapeutics, Inc.'s (NASDAQ:TNGX) 29% Share Price Gain Is Not Telling You

Tango Therapeutics, Inc. ( NASDAQ:TNGX ) shares have continued their recent momentum with a 29% gain in the last month...
Analysis Article • Jun 29

Subdued Growth No Barrier To Tango Therapeutics, Inc. (NASDAQ:TNGX) With Shares Advancing 27%

Tango Therapeutics, Inc. ( NASDAQ:TNGX ) shares have had a really impressive month, gaining 27% after a shaky period...
Analysis Article • May 30

Shareholders May Not Be So Generous With Tango Therapeutics, Inc.'s (NASDAQ:TNGX) CEO Compensation And Here's Why

Key Insights Tango Therapeutics will host its Annual General Meeting on 5th of June Salary of US$626.0k is part of CEO...
Analysis Article • Mar 19

Risks Still Elevated At These Prices As Tango Therapeutics, Inc. (NASDAQ:TNGX) Shares Dive 30%

Tango Therapeutics, Inc. ( NASDAQ:TNGX ) shares have had a horrible month, losing 30% after a relatively good period...
Analysis Article • Mar 06

Tango Therapeutics (NASDAQ:TNGX) Is In A Good Position To Deliver On Growth Plans

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, Tango Therapeutics...
Analysis Article • Jan 08

Tango Therapeutics, Inc.'s (NASDAQ:TNGX) Share Price Could Signal Some Risk

You may think that with a price-to-sales (or "P/S") ratio of 25x Tango Therapeutics, Inc. ( NASDAQ:TNGX ) is a stock to...
Analysis Article • Nov 09

Industry Analysts Just Upgraded Their Tango Therapeutics, Inc. (NASDAQ:TNGX) Revenue Forecasts By 15%

Shareholders in Tango Therapeutics, Inc. ( NASDAQ:TNGX ) may be thrilled to learn that the analysts have just delivered...
Analysis Article • Aug 12

New Forecasts: Here's What Analysts Think The Future Holds For Tango Therapeutics, Inc. (NASDAQ:TNGX)

Tango Therapeutics, Inc. ( NASDAQ:TNGX ) shareholders will have a reason to smile today, with the analysts making...
Analysis Article • May 10

Will Tango Therapeutics (NASDAQ:TNGX) Spend Its Cash Wisely?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...

CEO

Malte Peters (64 yo)

less than a year
Tenure
US$1,151,381
Compensation

Dr. Malte Peters, MD., is Director at HOOKIPA Pharma Inc. since 2023 and is its Chief Executive Officer since July 22, 2024 and served as its Ad Interim Senior Clinical Advisor from September 2023 until Ma...

Leadership Team

NamePositionTenureCompensationOwnership
Barbara Weber
Founder & Executive Chairman of the Board9.3yrsUS$2.82m1.07%
$ 47.3m
Malte Peters
Presidentless than a yearUS$1.15m0.0078%
$ 343.5k
Daniella Beckman
Executive Officerless than a yearUS$1.16m0.091%
$ 4.0m
Adam Crystal
President of Research & Development3.4yrsUS$1.72m0.012%
$ 525.8k
Alan Ashworth
Founder & Member of Scientific Advisory Boardno datano datano data
William Kaelin
Founder & Member of Scientific Advisory Boardno datano datano data
Antoni Ribas
Founder & Member of Scientific Advisory Boardno datano datano data
Matthew Gall
Chief Financial Officerless than a yearno datano data
Jannik Andersen
Chief Scientific Officer2.8yrsno datano data
Elizabeth Hickin
VP of IR & Corporate Communications1.3yrsno datano data
Julie Fogarty
Vice President of Legal & Corporate Secretaryno datano datano data
Julie Carretero
Chief Human Resources Officer2.3yrsno datano data
1.3yrs
Average Tenure
59yo
Average Age

Experienced Management: TNGX's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
Barbara Weber
Founder & Executive Chairman of the Board9.3yrsUS$2.82m1.07%
$ 47.3m
Malte Peters
President7.8yrsUS$1.15m0.0078%
$ 343.5k
Alan Ashworth
Founder & Member of Scientific Advisory Board5.5yrsno datano data
William Kaelin
Founder & Member of Scientific Advisory Board5.5yrsno datano data
Antoni Ribas
Founder & Member of Scientific Advisory Board5.5yrsno datano data
Mace Rothenberg
Independent Director5.3yrsUS$169.70k0.026%
$ 1.1m
Robert Azelby
Independent Directorless than a yearno datano data
Lesley Calhoun
Independent Director5.3yrsUS$176.33k0.0086%
$ 381.4k
John Ketchum
Independent Director2.9yrsUS$196.14k0.012%
$ 537.3k
Sung Lee
Lead Independent Directorless than a yearno data0%
$ 0
Alan Huang
Member of Scientific Advisory Board1.5yrsUS$1.88mno data
5.3yrs
Average Tenure
64yo
Average Age

Experienced Board: TNGX's board of directors are considered experienced (5.3 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/10 17:38
End of Day Share Price 2026/07/10 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Tango Therapeutics, Inc. is covered by 14 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Yuan ZhiB. Riley Securities, Inc.
John NewmanCanaccord Genuity
Eric SchmidtCantor Fitzgerald & Co.